Firefly Neuroscience Launches ATM Equity Program to Fund Growth

Firefly Neuroscience ( (AIFF) ) has issued an update.

On February 3, 2026, Firefly Neuroscience launched a $7.43 million at-the-market equity program with Konik Capital Partners to bolster working capital, offering flexibility to issue shares on Nasdaq while paying a 2% commission and standard indemnities; the company is free to halt sales before reaching the cap. The next day, its Israeli subsidiary amended CTO Gil Issachar’s employment terms by swapping his automatic annual bonus for a discretionary award up to one month’s salary and agreeing to settle bonuses accrued through December 31, 2025, signaling a shift toward performance-aligned compensation while resolving outstanding obligations.

The most recent analyst rating on (AIFF) stock is a Hold with a $0.82 price target. To see the full list of analyst forecasts on Firefly Neuroscience stock, see the AIFF Stock Forecast page.

Spark’s Take on AIFF Stock

According to Spark, TipRanks’ AI Analyst, AIFF is a Neutral.

The score is driven primarily by weak financial fundamentals—very large losses and ongoing cash burn—despite strong recent revenue growth and improved gross margin. Technicals are also bearish with the stock well below key moving averages and negative MACD, while valuation offers limited support due to negative earnings and no dividend. The warrant restructuring is a small liquidity positive but highlights continued reliance on external capital.

To see Spark’s full report on AIFF stock, click here.

More about Firefly Neuroscience

Firefly Neuroscience, Inc. operates in the neurotechnology sector, developing diagnostic and therapeutic tools that leverage neuroscience and data analytics, with its capital markets activities focused on sustaining product development and commercialization efforts.

Average Trading Volume: 149,053

Technical Sentiment Signal: Strong Sell

Current Market Cap: $11.55M

For detailed information about AIFF stock, go to TipRanks’ Stock Analysis page.